Is Fabino Enter overvalued or undervalued?

As of 22 September 2025, the valuation grade for Fabino Enter has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued in the current market context. Key ratios include a PE Ratio of 5.35, an EV to EBIT of 6.75, and a Price to Book Value of 1.25, which are significantly lower than many peers in the pharmaceuticals and biotechnology sector.
When compared to peers, Fabino Enter's PE Ratio of 5.35 is notably lower than Sun Pharma's 34.24 and Divi's Lab's 70.06, both categorized as expensive and very expensive, respectively. This suggests that while Fabino Enter is currently overvalued, it may still present a more attractive entry point relative to its peers. Additionally, the company's performance has lagged behind the Sensex, with a year-to-date return of -22.55% compared to the Sensex's positive return of 5.15%.